Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection

Taiwan J Obstet Gynecol. 2009 Sep;48(3):245-8. doi: 10.1016/S1028-4559(09)60297-7.

Abstract

Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome.

Materials and methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes.

Results: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.

Conclusion: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Embryo Implantation / drug effects*
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Luteal Phase / physiology*
  • Luteolytic Agents / pharmacology*
  • Ovulation Induction / methods
  • Placebos
  • Pregnancy
  • Pregnancy Rate
  • Sperm Injections, Intracytoplasmic / methods*
  • Treatment Outcome
  • Triptorelin Pamoate / pharmacology*

Substances

  • Luteolytic Agents
  • Placebos
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone